<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03630770</url>
  </required_header>
  <id_info>
    <org_study_id>WIH 13-0088</org_study_id>
    <nct_id>NCT03630770</nct_id>
  </id_info>
  <brief_title>Effect of Medium Chain Triglyceride Intake on Colonization of Preterm Infants With Candida</brief_title>
  <official_title>Effect of Medium Chain Triglyceride Intake on Colonization of Preterm Infants With Candida</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joseph Bliss</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Women and Infants Hospital of Rhode Island</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether adding a dietary supplement similar to coconut oil (MCT oil) to
      feedings in premature infants will reduce the amount of yeast (Candida) detectable in their
      stool. Infants who have Candida in their stool are eligible to participate. Half of the
      enrolled infants will have additional MCT oil added to their feedings and half will not.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2014</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stool fungal burden</measure>
    <time_frame>Before supplementation, 1 week after supplementation begins, 3 weeks (at conclusion of supplementation)</time_frame>
    <description>Change in colony-forming units (cfu) of Candida per gram of stool</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Candida Infection</condition>
  <condition>Premature Infant</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group receives no feeding supplement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MCT Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group is supplemented with MCT oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medium-Chain Triglyceride (MCT) Oil</intervention_name>
    <description>Infants receive 0.5 ml/oz of MCT oil to their prescribed feedings for 21 days or until hospital discharge.</description>
    <arm_group_label>MCT Oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premature infant admitted to the Neonatal Intensive Care Unit at Women &amp; Infants
             Hospital

          -  Receiving full enteral feeds of either preterm or transitional formula or fortified
             breast milk

          -  Anticipated to have a minimum stay of two weeks

        Exclusion Criteria:

          -  Prior exposure to antifungal drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph M Bliss, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women and Infants Hospital of Rhode Island</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph M Bliss, MD, PhD</last_name>
    <email>jbliss@wihri.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Women &amp; Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph M Bliss, MD, PhD</last_name>
      <email>jbliss@wihri.org</email>
    </contact>
    <investigator>
      <last_name>Joseph M Bliss, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gunsalus KT, Tornberg-Belanger SN, Matthan NR, Lichtenstein AH, Kumamoto CA. Manipulation of Host Diet To Reduce Gastrointestinal Colonization by the Opportunistic Pathogen Candida albicans. mSphere. 2015 Nov 18;1(1). pii: e00020-15. doi: 10.1128/mSphere.00020-15. eCollection 2016 Jan-Feb.</citation>
    <PMID>27303684</PMID>
  </reference>
  <results_reference>
    <citation>Arsenault AB, Gunsalus KTW, Laforce-Nesbitt SS, Przystac L, DeAngelis EJ, Hurley ME, Vorel ES, Tucker R, Matthan NR, Lichtenstein AH, Kumamoto CA, Bliss JM. Dietary Supplementation With Medium-Chain Triglycerides Reduces Candida Gastrointestinal Colonization in Preterm Infants. Pediatr Infect Dis J. 2019 Feb;38(2):164-168. doi: 10.1097/INF.0000000000002042.</citation>
    <PMID>29596218</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 25, 2018</study_first_submitted>
  <study_first_submitted_qc>August 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Women and Infants Hospital of Rhode Island</investigator_affiliation>
    <investigator_full_name>Joseph Bliss</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT03630770/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

